Kevin Outterson | |
|---|---|
| Alma mater | Northwestern University University of Reading |
| Occupation | Law professor |
| Employer | Boston University School of Law |
| Known for | Health Law, Intellectual Property Law, Antibiotic Resistance |
Kevin Outterson is a lawyer, a professor of law and the N. Neal Pike Scholar in Health and Disability Law at Boston University (2014–present).[1] He is also the founding executive director and principal investigator[2] of Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership that supports companies[3] developing new antibiotics, diagnostics, vaccines and other products to address drug-resistant bacterial infections. CARB-X is funded by[4] the United States, United Kingdom and German governments, Wellcome and the Bill & Melinda Gates Foundation. In 2022, CARB-X received a new commitment of funding[5] from BARDA and Wellcome of up to $370 million. The G7 Health Ministers have cited CARB-X[6] among the critical initiatives to support as the G7 governments renew their 2021 commitment to address the most dangerous drug-resistant infections.
Outterson's research focuses primarily on the law and economics of antibiotic resistance–including push and pull incentives–health law, intellectual property, and global access to medicine.[7]
Outterson has testified before Congress, the World Health Organization (WHO), UK Parliamentary working groups, and for the District of Columbia, Massachusetts, Vermont, California and West Virginia state legislatures.[8]
He is co-director of the health law program at Boston University School of Law (2007–present) and associate fellow at the Royal Institute of International Affairs at Chatham House,[9] London (2014–present). He served on the Board of the American Society of Law, Medicine & Ethics, and serves as faculty editor to the American Journal of Law & Medicine (2007–present). He is past editor-in-chief of the Journal of Law, Medicine & Ethics (2010–2016).[7]
References
- ^ "Kevin Outterson | School of Law". www.bu.edu. Retrieved 2022-08-24.
- ^ "KEVIN OUTTERSON, ESQ". Carb-X. Retrieved 2022-08-24.
- ^ "Overview". Carb-X. Retrieved 2022-08-24.
- ^ "Funding Partners". Carb-X. Retrieved 2022-08-24.
- ^ "CARB-X". May 19, 2022.
- ^ "G7 Health Ministers' Communiqué" (PDF). G7 Germany. May 20, 2022.
- ^ a b "Kevin Outterson | School of Law". www.bu.edu. Retrieved 12 May 2020.
- ^ "Boston University" (PDF). July 2015.
- ^ "Kevin Outterson". Chatham House – International Affairs Think Tank. Retrieved 2022-08-24.
External links
- Kevin Outterson publications indexed by Google Scholar
- "Racing the clock to stop drug-resistant superbugs" The Boston Globe by Maryn McKenna
- "Accelerating global innovation to address antibacterial resistance: introducing CARB-X" Nature Reviews Drug Discovery
- "Can we prevent antibiotic resistance?" The Brink by Robin Berghaus
- "Antibiotic-resistant infections could dwarf the COVID-19 pandemic" The Boston Globe by Kevin Outterson and Henry Skinner
- "A better way to fund the fight against superbugs" Bloomberg by James Paton
- "The battle against bugs" Boston Business Journal by Rowan Walrath
- "Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)" Progress, Potential, and Possibilities hosted by Ira Pastor
- "The Global Burden of AMR" Infectious Conversations hosted by Candace DeMatteis, Partnership to Fight Infectious Disease
- "Antibiotic Resistance: How CARB-X Helps New Companies Get a Running Start" The State of Health with Gunnar Esiason
| International | |
|---|---|
| National | |
| Academics | |
  | This American law–related biographical article is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 13 February 2024, at 20:12